Trends in intravenous antimicrobial start rates in outpatient hemodialysis centers, United States, 2012–2021
W. Wyatt Wilson, Hannah Hua, Qunna Li, Minn M. Soe, Ibironke W. Apata, Lu Meng, Jeneita M. Bell, Emily McDonald, Jonathan R. Edwards, Sarah Kabbani, Shannon Novosad
TL;DR
The use of intravenous antibiotics in outpatient dialysis centers in the U.S. has steadily decreased from 2012 through 2021, including during the early stages of the COVID-19 pandemic.
Contribution
This study provides the first comprehensive analysis of IV antimicrobial use trends in U.S. hemodialysis centers over nearly a decade.
Findings
Annual adjusted IVAS rates decreased by 6.64% from 2012 to March 2020.
IVAS rates further dropped by 8.91% from March 2020 to December 2021.
The decline in IVAS continued during the early phase of the COVID-19 pandemic.
Abstract
Using National Healthcare Safety Network data, an interrupted time series of intravenous antimicrobial starts (IVAS) among hemodialysis patients was performed. Annual adjusted rates decreased by 6.64% (January 2012–March 2020) and then further decreased by 8.91% until December 2021. IVAS incidence trends have decreased since 2012, including during the early COVID-19 pandemic.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntibiotic Use and Resistance · Central Venous Catheters and Hemodialysis · Antibiotics Pharmacokinetics and Efficacy